Phase II Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer

Inclusion Criteria: * Men aged ≥ 18 years * Histologically confirmed prostate cancer * Presence of skeletal metastasis (by CT or PET or MRI) * Disease progression documented by increasing PSA or two new lesions * Eastern Cooperative Oncology Group (ECOG) Performance status 0-2 Exclusion Criteria: * Confirmed brain and/or leptomeningeal metastases * Prior chemotherapy for prostate cancer * Peripheral neuropathy of Common Toxicity Criteria (CTC) grade 2 or greater * Other uncontrolled intercurrent illness * Treatment with immunotherapy against PCa * Clinically significant cardiovascular disease * Active autoimmune disease requiring treatment